Rebaseline no evidence of disease activity (NEDA-3) as a predictor of long-term disease course in a Norwegian multiple sclerosis population.

Cecilia Smith Simonsen,Heidi Øyen Flemmen,Line Broch, Kamilla Brekke,Cathrine Brunborg,Pål Berg-Hansen,Elisabeth Gulowsen Celius

Frontiers in neurology（2022）

引用 2|浏览6

暂无评分

摘要

NEDA-3 from rebaseline after 1 year, once treatment is stabilized, can predict the long-term disease course in MS. Starting a high efficacy DMT is associated with longer time to NEDA failure than moderate therapies. Finally, most pwMS only fail one component and new MRI lesions are the most likely cause of NEDA failure.

查看译文

关键词

NEDA 3,high efficacy treatment,multiple sclerosis,no evidence of disease activity,time to EDSS 6

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要